download BusinessFocus app
Golden Meditech Stem Cells 回應無端指控

Golden Meditech Stem Cells 回應無端指控

Market Information PR Newswire
By PR Newswire on 25 May 2022
PR Newswire (www.prnasia.com), a Cision company, is the premier global provider of media monitoring platforms and news distribution services that marketers, corporate communicators and investor relations professionals leverage to engage key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, distribute, target and measure text and multimedia content across traditional, digital, mobile and social channels. Combining the world's largest multi-channel content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and Asia-Pacific regions.

香港2022年5月25日 /美通社/ -- 2022 年 5 月 25 日,Golden Meditech Stem Cells (BVI) Company Limited("公司")謹就因公司行使與Blue Ocean Structure Investment Company Limited("Blue Ocean BVI")簽訂的《股權質押協議》項下權利而受到的指控作出回應。公司在行使權利後,為遵守監管義務於 2022 年 5 月 23 日向美國證券交易委員會提交了附表 13D。如有必要,公司可能會采取進一步的法律行動以保護自身利益。公司將確保在與Blue Ocean BVI之間正在進行的法律訴訟中將所有相關事實均提交法院審理,並期待法院對該爭議作出裁決。

【了解更多最快最新的財經、商業及創科資訊】

👉🏻 追蹤 WhatsApp 頻道 BusinessFocus

👉🏻 下載 BusinessFocus APP

👉🏻 立即Follow Instagram businessfocus.io

最新 金融投資熱話專頁 MarketFocus